Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
This study is testing whether adding an immunotherapy medicine called pembrolizumab to standard chemotherapy helps people with a common type of lung cancer live longer after surgery. Researchers want to see if helping your immune system fight remaining cancer cells works better than chemotherapy alone.
You may be able to join if you have stage II to IIIB non-small cell lung cancer that was successfully removed by surgery. Certain genetic requirements apply if you have non-squamous lung cancer, ensuring specific gene mutations are not present.
Participants will receive standard chemotherapy combined with pembrolizumab or have their health closely monitored over time. You will also undergo regular imaging scans, heart tests, give tissue and blood samples, and answer health questionnaires.
The study is currently recruiting participants at locations including Anchorage, Alaska, in the United States.
- 1Tests adding immunotherapy to standard chemotherapy after lung cancer surgery
- 2Involves regular check-ups, scans, and health questionnaires
- 3Currently looking for eligible participants to join
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.